Bauer B
So I wrote a little thing for @MolMetab sciencedirect.com/science/articl As we now appreciate, GLP-1 can target multiple brain regions and neuronal populations to reduce food intake, and the clinical results are increasingly impressive #obesity The ongoing SELECT trial will be pivotal for the field sciencedirect.com/science/articl From very modest weight loss with exenatide twice daily, the GLP-1 field has learned, by titration, dose escalation, higher Cmax, and better molecules, to achieve clinically meaningful #weightloss #T2D #obesity More progress to come #obesity described here sciencedirect.com/science/articl Beyond semaglutide and tirzepatide, where might we find the next GLP-1-based advances in #weightloss #obesity Take a look at the slope of the lines for the combination of cagrilintide + semaglutide and make projections out to 52 weeks thelancet.com/journals/lance Join the conversation
Whether it produces meaningfully better outcomes than once-daily dosing in humans remains unknown
Composed of 15 amino acids, this pentadecapeptide has been shown in research to stimulate angiogenesis, collagen formation, and tissue remodeling.- It may interact with nitric oxide pathways, growth factor expression, and inflammatory cascades to support endothelial function and cellular recovery.- Suggested mechanisms include upregulation of VEGF, engagement with FAK-paxillin signaling, and protective effects under oxidative stress conditions
Scientific Background of FOXO4-DRI FOXO4 belongs to the FOXO family of transcription factors responsible for regulating cellular stress responses, metabolism, and survival signaling
